Dyve Biosciences

Dyve Biosciences is pioneering a new class of therapies by using its DMAX transdermal delivery platform to systemically administer pH-modulating agents that are unsuitable for oral or injectable routes. The company's core innovation addresses the challenge of altering the acidic tumor microenvironment (TME) and other disease sites, which is known to drive cancer progression, immune evasion, and inflammation. With a completed Phase 2 proof-of-concept study and a pipeline targeting oncology and immunology, Dyve is positioning transdermal delivery as a legitimate third route for systemic drug administration. The company is led by an experienced team and is actively seeking partnerships to expand its therapeutic horizon.

DMAX transdermal platform: A proprietary emulsion technology that transiently fluidizes the skin's lipid matrix to enable systemic delivery of molecules unsuitable for oral or injectable routes, such as pH modulators.

Total raised: $20M

Dyve faces competition from companies developing TME-modulating drugs in oncology and established treatments for gout. Its main differentiation is the combination of a direct pH-modulation therapeutic strategy with a proprietary transdermal delivery platform that avoids the tolerability issues of oral alkalinizing agents.